RxDoctor Payments Data

Robert Kaufmann, MD

Internal Medicine · Atlanta, GANPI 1376573147

Payments from drug & device makers

$37,305in general payments, 2019–2025

Across 688 payments — averaging $54.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$13K
  • AbbVie$6K
  • Novo Nordisk AS$4K
  • AstraZeneca$3K
  • Novo Nordisk$3K
  • Amgen$1K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$2,04011%
  • Speaking & faculty fees$3,80021%
  • Travel & lodging$8214%
  • Food & beverage$11,83164%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ironwood Pharmaceuticals, Inc8$12,897
AbbVie(2 entities)104$6,401
Novo Nordisk AS1$4,000
AstraZeneca59$2,950
Novo Nordisk52$2,785
Amgen(2 entities)63$1,038
Johnson & Johnson52$777
GSK32$572
Novartis22$463
Abbott28$453
Lilly USA, LLC26$441
Kowa Pharmaceuticals America, Inc.12$363
Pfizer21$355
Boehringer Ingelheim15$288
Gilead12$261
Bayer12$230
Amarin Pharma, Inc.11$217
Astellas Pharma US Inc14$212
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$200
Merck11$162
Sanofi-aventis U.S. LLC6$119
Esperion Therapeutics, Inc.7$115
Dexcom, Inc.6$107
Takeda Pharmaceuticals U.S.A., Inc.5$102
Viiv Healthcare Company5$84
Corcept Therapeutics4$78
Merz North America, Inc.1$78
Tris Pharma Inc4$72
Jazz Pharmaceuticals Inc.3$63
Azurity Pharmaceuticals, Inc.4$62
Genentech USA, Inc.3$62
Biohaven Pharmaceutical Holding Company Ltd.3$61
Biogen3$60
Hikma Pharmaceuticals USA3$55
Vivus LLC6$55
Sunovion Pharmaceuticals Inc.4$54
Redhill Biopharma Inc.3$53
Insulet Corporation2$49
Otsuka America Pharmaceutical, Inc.2$48
Nestle Healthcare Nutrition Inc.3$46
Smith+Nephew1$46
Aytu Biopharma, Inc.3$45
Regeneron Healthcare Solutions, Inc.2$44
Noven Therapeutics, LLC2$43
Teva Pharmaceuticals USA, Inc.3$42
Aimmune Therapeutics, Inc.2$39
Ironshore Pharmaceuticals Inc.2$39
Shire North American Group Inc2$38
Supernus Pharmaceuticals, Inc.2$38
Idorsia Pharmaceuticals US Inc2$36
Arbor Pharmaceuticals, Inc.2$29
Avanir Pharmaceuticals, Inc.1$26
United Orthopedics LLC1$26
Eisai Inc.2$25
Paratek Pharmaceuticals, Inc.1$24
E.r. Squibb & Sons, L.L.C.2$24
Linus Health, Inc.1$22
Exact Sciences1$20
Vanda Pharmaceuticals Inc.1$20
Scynexis, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,305 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,008
Medicare patients
679
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$224,204
OzempicSemaglutide137$199,651
FarxigaDapagliflozin Propanediol85$95,134
JanuviaSitagliptin Phosphate38$62,334
XareltoRivaroxaban42$60,131
LinzessLinaclotide43$52,539
TrulicityDulaglutide36$46,124
MyrbetriqMirabegron41$46,023
JardianceEmpagliflozin35$45,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$38,753
MounjaroTirzepatide26$33,257
ShingrixVaricella-Zoster Ge/As01b/Pf65$14,219
VascepaIcosapent Ethyl20$13,463
Repatha SureclickEvolocumab19$12,566
TradjentaLinagliptin12$12,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$355$224,204192 claims
Novo NordiskOzempic$2,785$199,651137 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$2,950$104,682116 claims
Lilly USA, LLCTrulicity, Mounjaro$441$79,38162 claims
Johnson & JohnsonXarelto, Invokana$777$69,97957 claims
MerckJanuvia$162$62,33438 claims
AbbVieLinzess, Synthroid$6,401$57,31686 claims
Boehringer IngelheimJardiance, Tradjenta$288$57,27247 claims
GSKTrelegy Ellipta, Shingrix$572$52,972100 claims
Astellas Pharma US IncMyrbetriq$212$46,02341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →